Jose Sobrino Catoni
Hematology & Oncology · Fajardo, PRNPI 1174602064
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,058 of the $14,799 with a category attached, or 81.5%. 39 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.5% of the total. Reporting peaked in 2022 at $4,553 and has fallen 51.0% since, to $2,229 in 2025.
Across 596 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Merck$2K
- AstraZeneca$2K
- Johnson & Johnson$1K
- PBG Puerto Rico LLC$1K
- Eli Lilly Export S.A. Puerto Rico Branch$735
- plus $4K from 33 others
What the payments were for
- Consulting fees$1,50510%
- Speaking & faculty fees$1,1258%
- Food & beverage$12,05881%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 117 | $3,768 |
| Merck | 45 | $1,984 |
| AstraZeneca | 87 | $1,746 |
| Johnson & Johnson | 70 | $1,428 |
| PBG Puerto Rico LLC | 57 | $1,188 |
| Eli Lilly Export S.A. Puerto Rico Branch | 34 | $735 |
| Amgen | 24 | $529 |
| AbbVie | 23 | $504 |
| Novartis | 17 | $364 |
| Sanofi | 16 | $360 |
| Genentech USA, Inc. | 21 | $350 |
| GSK | 16 | $347 |
| Seagen Inc. | 8 | $163 |
| Puma Biotechnology, Inc. | 6 | $137 |
| Bristol Myers Squibb | 1 | $131 |
| Astellas Pharma US Inc | 5 | $114 |
| Incyte Corporation | 5 | $108 |
| Bayer | 5 | $99 |
| Bayer Puerto Rico Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $64 |
| Pfizer Pharmaceuticals LLC | 4 | $55 |
| Pfizer | 4 | $53 |
| Pharmaand GmbH | 2 | $46 |
| Stemline Therapeutics Inc. | 2 | $46 |
| Caris MPI, Inc. | 2 | $44 |
| Exelixis Inc. | 2 | $43 |
| Springworks Therapeutics, Inc. | 2 | $42 |
| Taiho Oncology, Inc. | 2 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Tolmar, Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $23 |
| Clovis Oncology, Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Array Biopharma Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,799 in reported general payments places this provider in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 89 | $1,962,133 |
| VerzenioAbemaciclib | 27 | $417,097 |
| ImbruvicaIbrutinib | 11 | $361,479 |
| KisqaliRibociclib Succinate | 11 | $191,295 |
| PromactaEltrombopag Olamine | 17 | $150,558 |
| RetacritEpoetin Alfa-Epbx | 11 | $19,647 |
| Aprepitant | 16 | $7,003 |
| Abiraterone Acetate | 23 | $5,467 |
| Exemestane | 25 | $1,725 |
| Anastrozole | 127 | $1,617 |
| Prochlorperazine Maleate | 41 | $1,044 |
| Dexamethasone | 29 | $674 |
| Ondansetron Hcl | 46 | $542 |
| Gabapentin | 21 | $299 |
| Prednisone | 33 | $297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $131 | $1,962,13389 claims |
| Lilly USA, LLCVerzenio | $64 | $417,09727 claims |
| NovartisKisqali, Promacta | $364 | $341,85328 claims |
| PfizerRetacrit | $53 | $19,64711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Fajardo
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Joel Lopez-FigueroaHumacao$163K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Carlos Mendez SerranoCaguas$91K
- Santa MerleMoca$84K
- Edgardo Santiago-GuzmanSan Juan$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.